Migraine Progression: A Systematic Review. An Editorial Comment

Dawn C. Buse; Jacob D. Greisman; Khosrow Baigi; Richard B. Lipton

doi:10.1111/head.13573

Migraine Progression: A Systematic Review. An Editorial Comment

Dawn C. Buse, Jacob D. Greisman, Khosrow Baigi, Richard B. Lipton

Neurology

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	974-976
Number of pages	3
Journal	Headache
Volume	59
Issue number	7
DOIs	https://doi.org/10.1111/head.13573
State	Published - Jul 1 2019

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1111/head.13573

Cite this

@article{8da63ecfeb1644808e27ce6accd9a1fb,

title = "Migraine Progression: A Systematic Review. An Editorial Comment",

author = "Buse, {Dawn C.} and Greisman, {Jacob D.} and Khosrow Baigi and Lipton, {Richard B.}",

note = "Funding Information: Disclosures: Dawn C. Buse, PhD, in the past 12 months, has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Promeius, and Teva. She is on the editorial board of Current Pain and Headache Reports. Jacob D. Greisman, BA has nothing to disclose. Khosrow Baigi, MD, MPH has nothing to disclose. Richard B. Lipton, MD is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy{\textquoteright}s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff{\textquoteright}s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = jul,

day = "1",

doi = "10.1111/head.13573",

language = "English (US)",

volume = "59",

pages = "974--976",

journal = "Headache",

issn = "0017-8748",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Migraine Progression

T2 - A Systematic Review. An Editorial Comment

AU - Buse, Dawn C.

AU - Greisman, Jacob D.

AU - Baigi, Khosrow

AU - Lipton, Richard B.

N1 - Funding Information: Disclosures: Dawn C. Buse, PhD, in the past 12 months, has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Promeius, and Teva. She is on the editorial board of Current Pain and Headache Reports. Jacob D. Greisman, BA has nothing to disclose. Khosrow Baigi, MD, MPH has nothing to disclose. Richard B. Lipton, MD is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85068965011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068965011&partnerID=8YFLogxK

U2 - 10.1111/head.13573

DO - 10.1111/head.13573

M3 - Editorial

C2 - 31297806

AN - SCOPUS:85068965011

VL - 59

SP - 974

EP - 976

JO - Headache

JF - Headache

SN - 0017-8748

IS - 7

ER -